Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Molecular Cancer Research - United States
doi 10.1158/1541-7786.mcr-17-0594
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Diffusion Kurtosis MRI as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy in High Grade Serous Ovarian Cancer

Scientific Reports
Multidisciplinary
2019English

External Validation of Chemotherapy Response Score System for Histopathological Assessment of Tumor Regression After Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma

Journal of Gynecologic Oncology
MedicineGynecologyOncologyObstetrics
2017English

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Erratum To: Tubal Precursor Lesions in High Grade Serous Ovarian Carcinoma

Indian Journal of Gynecologic Oncology
GynecologyOncologyObstetrics
2016English

Outcomes of Non-High Grade Serous Carcinoma After Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: A Korean Gynecologic Oncology Group Study (OV 1708)

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

HMGA2: A Biomarker Significantly Overexpressed in High-Grade Ovarian Serous Carcinoma

Modern Pathology
Forensic MedicinePathology
2010English

Integrated Analysis to Identify Molecular Biomarkers of High-Grade Serous Ovarian Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Amplification of the Ch19p13.2 NACC1 Locus in Ovarian High-Grade Serous Carcinoma

Modern Pathology
Forensic MedicinePathology
2011English

Characteristics of 10-Year Survivors of High-Grade Serous Ovarian Carcinoma

Gynecologic Oncology
GynecologyOncologyObstetrics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy